Physician profile
Nelson Leung
NPI 1356313910
$31,743.53
in general payments reported to CMS, 2019-2025
12 companies · $11K in 2025
The $11K reported for 2025 was more than what 95% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $1,250 · 2021: $4,439 · 2022: $103 · 2024: $2,460 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,605 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,345 · Food and Beverage: $1,077 · Travel and Lodging: $1,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,605.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,345.00 |
| Food and Beverage | $1,076.80 |
| Travel and Lodging | $1,030.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $12,775.00 | 2019 | |
| Alexion Pharmaceuticals, INC. | $6,197.50 | 2025 | Ultomiris |
| Genzyme Corporation | $3,586.66 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,600.00 | 2025 | |
| Omeros Corporation | $2,205.21 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $2,018.00 | 2019-2024 | |
| Orion Corporation | $1,800.00 | 2025 | |
| Janssen Global Services, LLC | $352.50 | 2024 | Tecvayli |
| Novartis Pharmaceuticals Corporation | $126.80 | 2024 | |
| Abbvie INC. | $56.36 | 2019 | |
| Legend Biotech USA INC. | $25.50 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nelson Leung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.